Pharmaceuticals, Biotechnology and Life Sciences
EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies…
– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs…
Phase 1b/2a Study Expected to Begin In 2Q 2021DELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc.…
– Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational…
Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK Reported Positive Pre-Clinical Data Associated with…
– Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in…
Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in…
Growing body of in vitro data support Brilacidin’s potential as a broad-spectrum inhibitor of virusesBrilacidin is currently undergoing Phase 2…
OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed…
SANTA ANA, Calif., April 07, 2021 (GLOBE NEWSWIRE) — NKGen Biotech, a biotechnology company harnessing the power of the body’s…